PharmD Program Associate - Regulatory Labeling and Advertising Promotion
Regeneron Pharmaceuticals
Summary
The PharmD Program is an intensive, interdisciplinary program for graduating PharmD and/or PhD candidates. The program consists of training by Regeneron mentors and experience leading projects in various global development roles. This unique program provides participants depth and breadth of experience within Regeneron's Global Development organization through diverse training, cross-functional experiences, and ongoing mentorship. Assignments in this 2-year development program will expose candidates to critical issues and decision-making processes, acquire high-level knowledge of the business and department operations, and gain hands-on work experience in different areas.
Job description
Program Overview
The PharmD Program is an intensive, interdisciplinary program for graduating PharmD and/or PhD candidates. The program consists of training by Regeneron mentors and experience leading projects in various global development roles. This unique program provides participants depth and breadth of experience within Regeneron's Global Development organization through diverse training, cross-functional experiences, and ongoing mentorship. Assignments in this 2-year development program will expose candidates to critical issues and decision-making processes, acquire high-level knowledge of the business and department operations, and gain hands-on work experience in different areas.
Regulatory Labeling & Advertising/Promotion Track
Associate will contribute to the development of labeling content and labeling strategies through interpretation of regulations and guidelines; and support the labeling process throughout the product lifecycle, including Labeling Working Group reviews and management approvals. The associate will also develop knowledge and skills to interpret FDA regulations and guidances to ensure promotional communications are truthful and not misleading, and appropriately advise teams on associated regulatory risks, and support FDA-Office of Prescription Drug Promotion (OPDP) interactions.
Responsibilities
- Drafting documents integral to clinical sites and regulatory submissions
- Analyzing data from clinical studies in preparation for interactions with ethics committees, senior management, regulatory authorities, and others
- Managing third-party vendors and maintaining timelines of key results
- Developing regulatory strategies for clinical development programs
- Analyzing safety data to characterize the safety profile of products throughout their development lifecycle
- Working with program mentors to improve skills to reach professional goals better
- Opportunities to travel to clinical sites and/or meetings with health authorities
Requirements
- Post-doctoral graduates from an accredited (ACPE) College of Pharmacy program (PharmD); PhD graduates within a life science related area of study may also be considered
- Must have completed PharmD and/or PhD degree by Summer 2027
- Prior internship or rotational experience within the Pharmaceutical/Biotech industry a plus
- Exposure or familiarity with evaluating clinical trials, scientific literature and data
- Highly motivated and seeking to build a career with a foundation in Clinical Sciences, Global Clinical Operations, Regulatory Affairs, and/or Safety Sciences
- Eligible to work in the U.S. on a permanent basis
Benefits
- Annual Bonuses
- Incentive Plans
- Equity Awards
- Pension/Retirement Benefits
- 401(k) Matching
- Health & Wellness Programs
- Fitness Centers
- Medical, Dental & Vision
- Life & Disability Insurance
- Paid Time Off
- Family Support Benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.